An oral supplementation based on myo-inositol, folic acid and liposomal magnesium may act synergistically with antibiotic therapy and can improve metabolic profile in patients affected by Hidradenitis suppurativa: our experience.

BACKGROUND: Over recent years, the link between obesity, metabolic syndrome and Hidradenitis suppurativa (HS) has been explored. It has been demonstrated that HS patients have a high prevalence of the metabolic syndrome and an increased frequency of insulin resistance. The objective of our study is to estimate the effectiveness of an oral supplementation based on myo-inositol (MI), folic acid and liposomal magnesium (Levigon®, Sanitpharma; Milan, Italy) on the clinical and metabolic profile of patients affected by HS. METHODS: Twenty subjects with HS and an impaired glucose metabolism were enrolled. Group A: 10 subjects received for 6 months MI 2000 mg, liposomal magnesium and folic acid associated to topical antibiotic therapy (clindamycin gel 1%), systemic antibiotic therapy (clindamycin 300 mg b.i.d. and rifampicin 600 mg daily for 6 weeks) and a normocaloric diet group B: 10 subjects received topical and systemic antibiotic therapy associated to a normocaloric diet for 6 months. RESULTS: After 6 months group A patients showed an average reduction of Sartorius Score from 38.3±7.75 to 27.3±13.53 (P value <0.04) while in the control group there was a reduction of the Sartorius from 38.4±7.88 to 31.1±8.02 (P value =0.55). Moreover in group A Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was significantly reduced from 2.43±0.35 to 2.1±0.31 (P<0.01) whereas in group B HOMA-IR did not significantly decrease (2.51±0.65 at T0 at 2.40±0.67 at T1). CONCLUSIONS: Our study underlines the importance of the evaluation of metabolic profile in patients with HS. Moreover, it suggests that the supplementation of MI, folic acid and liposomal magnesium in HS can improve the efficacy of concomitant therapies and the metabolic profile.

Evaluation of tolerability and skin changes after application of topical antiaging products based on Sibanid SG®, plant stem cells and regenerative and biostimulating active ingredients.

BACKGROUND: The oxidative stress, the UV radiations, the matrix metalloproteinases (MMPs) and the hyaluronidase enzyme play an extremly important role in skin aging processes, leading an increasing production of elastase, collagenase and hyaluronidase that brings to degradation of collagen, elastin and hyaluronic acid respectively. They are responsible to provide strength, elasticity and moisture to the skin. Innovative devices were developed based on the effective ingredients against hyaluronidase and MMP. The inhibition of the destructuring enzymes of the dermis is the main mechanism of action of Bioliftan treatment, and this process is mainly addressed to hyaluronidase and MMP inhibition. The aim of our study was to evaluate the efficacy, tolerability and skin changes induced by antiaging topical based on Sibanid SG®, plant stem cells and regenerative and biostimulating active ingredients. The products tested are Bioliftan Day cream and Bioliftan concentrate. METHODS: All parameters were evaluated before the beginning of treatment (T0), and 60 (T1) days later. The evaluation of the effectiveness of the products was performed by clinical examination, photographic and instrumental documentation by corneometry, X-rite, elastometry, Moisture Meter EpiD, Confocal microscopy. RESULTS: The products tested after 60 days have induced an increase of hydration of the external cutaneous layers (P<0.0001), skin hydration (P<0.0001), skin brightness (P<0.01), skin elasticity (P<0.0001). All results were statistically significant. All volunteers completed the study. No patients reported side-effects. All results were confirmed by confocal microscopy. CONCLUSIONS: Our study evaluated efficacy, tolerability and skin changes after 60 days of Bioliftan day cream and Bioliftan serum concentrate application on the skin aged. Our study has shown an excellent skin tollerance of the products tested.